表紙
市場調查報告書
商品編碼
1087836

全球MRD(最小殘留疾病)檢測市場(2022-2027 年):按技術、應用、最終用戶和地區劃分

MRD Testing Market - A Global and Country Analysis: Focus on Technology, Application, End User, Region - Analysis and Forecast, 2022-2027

出版日期: | 出版商: BIS Research Inc. | 英文 281 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球最小殘留疾病 (MRD) 檢測市場將從 2021 年的 10.893 億美元增長到預測期內的 14.53% 的複合年增長率,並將在 2027 年增長到 26.112 億美元。

血液系統惡性腫瘤發病率增加、消費者對量身定制治療的意識增強、國家癌症中心研究經費增加以及新興國家可支配收入增加等因素都是市場因素。

本報告調查了全球 MRD(最小殘留疾病)檢測市場,定義和概述了市場,分析了對市場增長、法律和監管環境、贖回情景以及市場規模變化的各種影響因素。類別/地區/主要國家、競爭環境、主要公司概況等匯總。

目錄

第 1 章市場

第二章調查方法

第三章市場概述

  • MRD檢驗:簡介
  • MRD測試:實體瘤和血液系統惡性腫瘤
  • 市場足跡
  • 市場規模/未來增長潛力

第四章市場動態

  • 影響分析
  • 市場促進因素
  • 市場製約因素
  • 市場機會

第5章工業考慮

  • 審批場景
  • 融資場景
  • 監管框架
  • 兌換場景
  • 供應鏈分析
  • 價格敏感性分析(彈性)

第 6 章全球 MRD(最小火星)測試市場:競爭考慮

  • 概覽
  • 協同活動
  • 產品認證
  • 產品發布和更新
  • 併購
  • 業務擴張/融資
  • 其他發展
  • 市場份額分析
  • 增長份額分析

第7章全球MRD(Minimal Mars)測試市場:利益相關者分析

  • 醫生的認可
  • 保險公司認可
  • 投資者意識

第 8 章全球 MRD(最小火星)測試市場:按技術分類

  • 概覽
  • 流式細胞儀
  • 聚合□鍊式反應 (PCR)
  • 下一代測序 (NGS)
  • 其他

第 9 章全球 MRD(最小火星)測試市場:按應用程序

  • 概覽
  • 血液系統惡性腫瘤
    • 非霍奇金淋巴瘤 (NHL)
    • 多發性骨髓瘤 (MM)
    • 急性淋巴細胞白血病(ALL)
    • 慢性淋巴細胞白血病(CLL)
    • 急性髓性白血病 (AML)
    • 慢性粒細胞白血病(CML)
    • 霍奇金淋巴瘤(HL)
    • 其他白血病

第 10 章全球 MRD(最小火星)測試市場:按最終用戶分類

  • 概覽
  • 醫院/專科診所
  • 診斷實驗室
  • 研究所
  • 其他

第 11 章全球 MRD(最小火星)測試市場:按地區劃分

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東
  • 其他領域

第 12 章公司簡介

  • ICON plc
  • ARUP Laboratories
  • Cergentis B.V.
  • Bio-Rad Laboratories, Inc.
  • Mission Bio, Inc.
  • Guardant Health
  • Invivoscribe, Inc.
  • Laboratory Corporation of America Holdings
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health, Inc.
  • Quest Diagnostics Incorporated
  • Sysmex Corporation
  • Adaptive Biotechnologies Corporation
  • F. Hoffmann-La Roche Ltd
目錄
Product Code: BHP1013SB

“Global Minimal Residual Disease (MRD) Testing Market to Reach $2,611.2 Million by 2027.”

Global MRD Testing Market: Industry Overview

The minimal residual disease (MRD) testing market is projected to reach $2,611.2 million by 2027 from $1,089.3 million in 2021, at a CAGR of 14.53%. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, increasing consumer awareness for tailored therapy, increasing research funding from the National Cancer Institute and increasing disposable income in emerging economies.

Market Lifecycle Stage

The global MRD testing market is in the rapidly evolving and dynamic stage, which opens ample opportunities for diagnostic and life science companies. Also, companies that are already in the development phase for MRD tests are trying to match themselves with modern technologies in the market to improve the overall system of MRD testing, from diagnostic assays and kits development to commercialization. The companies operating in the global MRD testing market are now focusing more on disease-specific and personalized diagnostic kits to enhance testing and improve detection outcomes. Also, major players such as ARUP Laboratories, Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Cergentis B.V, F. Hoffmann-La Roche Ltd, and Guardant Health are investing heavily in research and development for their respective testing products.

Impact

With an increased worldwide focus on treating hematological malignancies, the major market players are developing novel diagnostic tests, which are significantly impacting the growth of the MRD testing market. Diagnostic evolution in the form of companion diagnostics and liquid biopsy through molecular techniques such as PCR and NGS has enabled molecular diagnostic juggernauts to enter this market seamlessly. Following FDA approvals of clonoSEQ and Signatera, major companies are now looking to invest in the field of MRD, focusing primarily on the foundation laid for hematological malignancies. The market witnessed approximately 35 significant synergistic developments during the time period between January 2018 and May 2022.

In addition to this, in November 2021, Palmetto GBA's Molecular Diagnostics Program (MolDX) has confirmed a local coverage determination that supported the Medicare coverage for Adaptive Biotechnologies clonoSEQ in patients with B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL) for monitoring minimal residual disease. The above activities created a global impact and contributed to an increase in MRD testing market.

Market Segmentation

Segmentation 1: by Technology

  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Other Technologies

Due to recent developments in molecular diagnostic technologies, the turnaround time and overall cost have been reduced with increased sensitivity and accuracy of results. Significant advances are being witnessed in the development of highly sensitive, quantitative, and multiplex assays. Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing.

Segmentation 2: by Application

  • Hematological Malignancy
  • Solid Tumor

The global MRD testing market (by application) is broadly segmented into hematological malignancy and solid tumor applications. The global MRD testing market (by application) is dominated by hematological malignancy, which held a share of 94.39% in 2021.

Segmentation 3: by End User

  • Hospital and Specialty Clinics
  • Diagnostic Laboratories
  • Research Institutions
  • Other End Users

End users of the MRD market typically include hospitals and specialty clinics, research institutions, diagnostic laboratories, and others. Although hospitals and specialty clinics have been at the forefront of developing advanced technologies that incorporate several ancillaries for superior biological and chemical research, the applicability of MRD tests has been widespread among research institutions. Other end users, such as out-patient clinics and cancer clinics, also contribute significantly to the global MRD testing market.

Segmentation 4: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • Italy
    • France
    • U.K.
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Rest-of-APAC (RoAPAC)
  • Latin America and Middle East
    • Brazil
    • Mexico
    • Saudi Arabia
    • Rest-of-Latin America and Middle East
  • Rest-of-the-World (RoW)

In 2021, North America accounted for a share of 42.92% of the global minimal residual disease testing market. The segment is expected to reach $1,016.8 million in 2027 from $467.5 million in 2021 at a CAGR of 12.68% during the forecast period 2022-2027.

Recent Developments in the Global MRD Testing Market

  • In November 2021, Palmetto GBA's Molecular Diagnostics Program (MolDX) confirmed a local coverage determination that supported the Medicare coverage for clonoSEQ in patients with B-cell acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL) for monitoring minimal residual disease.
  • In February 2021, Natera, Inc. and Personalis, Inc. partnered in the field of personalized oncology by combining Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment.
  • In May 2021, Invivoscribe, Inc. announced licensing of key software and two new MRD clinical services. The company's LymphoTrack Enterprise Software supported high volume customers to meet ever-increasing testing demands.
  • In October 2021, Inivata Limited, a subsidiary of NeoGenomics, Inc. entered a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata's InVisionFirst-Lung and RaDaR liquid biopsy assays in two separate studies.

Demand - Drivers and Limitations

Following are the demand drivers for the global MRD testing market:

  • Rising Incidence of Hematological Malignancies
  • Increasing Consumer Awareness for Tailored Therapy
  • Increase in Research Funding from National Cancer Institute
  • Increasing Disposable Income in Emerging Economies

The market is expected to face some limitations too due to the following challenges:

  • False Negatives and Positives
  • Uncertain Reimbursement and Regulatory Policies
  • Lack of Trained Professionals
  • Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies

How can this report add value to an organization?

  • Technology/Innovation Strategy: The technology segment helps the reader understand the different technology based on MRD testing present in the market. Moreover, the study provides the reader with a detailed understanding of two different applications including hematologic malignancy and solid tumor.
  • Growth/Marketing Strategy: The global MRD testing market has seen major development by key players operating in the market, such as synergistic activities, product approvals, product launches and updates, mergers and acquisitions, business expansion and funding, and other developments (Medicare coverage). The favored strategy for the companies has been regulatory and legal activities along with product approvals to strengthen their position in the market.
  • Competitive Strategy: Key players in the global MRD testing market have been analyzed and profiled in the study. Moreover, a detailed competitive benchmarking of players operating in the global MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Total Number of Companies Profiled: 15 (11 public companies and 4 private companies).

Public companies include: ICON plc, Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, Sysmex Corporation, Quest Diagnostics Incorporated, Opko Health, Inc., NeoGenomics Laboratories, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche, and Guardant Health. The private company profiled are ARUP Laboratories, Cergentis B.V., Invivoscribe, Inc., and Mission Bio, Inc.

Table of Contents

1 Market

  • 1.1 Product Definition and Market Scope
  • 1.2 Inclusion and Exclusion
  • 1.3 Scope of Work
  • 1.4 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Global MRD Testing Market: Research Methodology
  • 2.2 Primary Data Sources
  • 2.3 Secondary Data Sources
  • 2.4 Market Estimation Model
  • 2.5 Criteria for Company Profiling

3 Market Overview

  • 3.1 MRD Testing: Introduction
  • 3.2 MRD Testing: Solid Tumor vs. Hematological Malignancy
  • 3.3 Market Footprint
  • 3.4 Market Size and Future Growth Potential

4 Market Dynamics

  • 4.1 Impact Analysis
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Hematological Malignancies
    • 4.2.2 Increasing Consumer Awareness for Tailored Therapy
    • 4.2.3 Increase in Research Funding from National Cancer Institute
    • 4.2.4 Increasing Disposable Income in Emerging Economies
  • 4.3 Market Restraints
    • 4.3.1 False Negatives and Positives
    • 4.3.2 Uncertain Reimbursement and Regulatory Policies
    • 4.3.3 Lack of Trained Professionals
    • 4.3.4 Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies
  • 4.4 Market Opportunities
    • 4.4.1 Potential Long-Term Cost Savings
    • 4.4.2 Increasing Market Access in Emerging Economies
    • 4.4.3 Technological Evolution of Testing
      • 4.4.3.1 10- and 12-Color Flow Cytometry
      • 4.4.3.2 PCR for Gene Rearrangements
      • 4.4.3.3 NGS and Multiplexing

5 Industry Insights

  • 5.1 Approval Scenario
    • 5.1.1 Approved Minimal Residual Disease Tests by Major Players
    • 5.1.2 Launched Minimal Residual Disease Tests (by Major Players)
  • 5.2 Financing Scenario
    • 5.2.1 Key Players' Stratification (as Per Raised Financing Value)
    • 5.2.2 Key Players' Financing Analysis (FY2019-2021)
  • 5.3 Regulatory Framework
    • 5.3.1 Legal Requirements and Framework in the U.S.
    • 5.3.2 Legal Requirements and Framework in Europe
    • 5.3.3 Legal Requirements and Framework in Asia-Pacific
      • 5.3.3.1 Japan
      • 5.3.3.2 China
      • 5.3.3.3 India
  • 5.4 Reimbursement Scenario
    • 5.4.1 North America
      • 5.4.1.1 Outpatient Department (OPD) vs. Inpatient Department (IPD)
    • 5.4.2 European Union
      • 5.4.2.1 OPD vs. IPD
    • 5.4.3 Asia-Pacific
  • 5.5 Supply Chain Analysis
    • 5.5.1 For Laboratory Developed Tests (LDTs)
    • 5.5.2 For In-Vitro Diagnostics (IVDs)
  • 5.6 Price Sensitivity Analysis (Elasticity)
    • 5.6.1 Physicians' Perception
      • 5.6.1.1 Turnaround Time (TAT)
      • 5.6.1.2 Test Sensitivity
    • 5.6.2 Investors' Perception
      • 5.6.2.1 Turnaround Time (TAT)
      • 5.6.2.2 Test Sensitivity
    • 5.6.3 Payors' Perception
      • 5.6.3.1 Turnaround Time (TAT)
      • 5.6.3.2 Test Sensitivity

6 Global Minimal Residual Disease Testing Market: Competitive Insights

  • 6.1 Overview
  • 6.2 Synergistic Activities
  • 6.3 Product Approvals
  • 6.4 Product Launches and Updates
  • 6.5 Merger and Acquisition Activities
  • 6.6 Business Expansion and Funding Activities
  • 6.7 Other Developments
  • 6.8 Market Share Analysis, 2020-2021
  • 6.9 Growth-Share Analysis
    • 6.9.1 Growth-Share Analysis (by Company)
    • 6.9.2 Growth-Share Analysis (by Technology)
    • 6.9.3 Growth-Share Analysis (by Application)
    • 6.9.4 Growth-Share Analysis (by End User)

7 Global Minimal Residual Disease Testing Market: Stakeholder Analysis (N=30-40)

  • 7.1 Physicians' Perception
    • 7.1.1 Stage of the Treatment Use for MRD
    • 7.1.2 Frequency of Receiving MRD Testing
    • 7.1.3 Average Treatment Duration for Patients Diagnosed with MRD
    • 7.1.4 Adoption and Barriers to MRD Testing
  • 7.2 Payors' Perception
    • 7.2.1 Reimbursement vs. Patient Out-of-Pocket Expense
  • 7.3 Investors' Perception
    • 7.3.1 Price vs. Sensitivity vs. Turnaround time

8 Global Minimal Residual Testing Market (by Technology), 2021-2027

  • 8.1 Overview
  • 8.2 Flow Cytometry
  • 8.3 Polymerase Chain Reaction (PCR)
  • 8.4 Next-Generation Sequencing (NGS)
  • 8.5 Other Technologies

9 Global Minimal Residual Testing Market (by Application), 2021-2027

  • 9.1 Overview
  • 9.2 Hematological Malignancy
    • 9.2.1 Non-Hodgkin's Lymphoma (NHL)
      • 9.2.1.1 Non-Hodgkin's Lymphoma (NHL) (by Type)
      • 9.2.1.2 Non-Hodgkin's Lymphoma (NHL) (by Age)
    • 9.2.2 Multiple Myeloma (MM)
      • 9.2.2.1 Multiple Myeloma (MM) (by Age)
    • 9.2.3 Acute Lymphoblastic Leukemia (ALL)
      • 9.2.3.1 Acute Lymphoblastic Leukemia (ALL) (by Age)
    • 9.2.4 Chronic Lymphocytic Leukemia (CLL)
      • 9.2.4.1 Chronic Lymphocytic Leukemia (CLL) (by Age)
    • 9.2.5 Acute Myeloid Leukemia (AML)
      • 9.2.5.1 Acute Myeloid Leukemia (AML) (by Age)
    • 9.2.6 Chronic Myeloid Leukemia (CML)
      • 9.2.6.1 Chronic Myeloid Leukemia (CML) (by Age)
    • 9.2.7 Hodgkin's Lymphoma (HL)
      • 9.2.7.1 Hodgkin's Lymphoma (HL) (by Age)
    • 9.2.8 Other Leukemia

10 Global Minimal Residual Disease Testing Market (by End User), 2021-2027

  • 10.1 Overview
  • 10.2 Hospitals and Specialty Clinics
    • 10.2.1 Hospitals and Specialty Clinics (by Technology)
  • 10.3 Diagnostic Laboratories
    • 10.3.1 Diagnostic Laboratories (by Technology)
  • 10.4 Research Institutions
    • 10.4.1 Research Institutions (by Technology)
  • 10.5 Other End Users
    • 10.5.1 Other End Users (by Technology)

11 Global Minimal Residual Disease Testing Market (by Region), 2021-2027

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
      • 11.2.1.1 U.S. Minimal Residual Disease Testing Market (by Application)
    • 11.2.2 Canada
      • 11.2.2.1 Canada Minimal Residual Disease Testing Market (by Application)
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Germany Minimal Residual Disease Testing Market (by Application)
    • 11.3.2 Italy
      • 11.3.2.1 Italy Minimal Residual Disease Testing Market (by Application)
    • 11.3.3 France
      • 11.3.3.1 France Minimal Residual Disease Testing Market (by Application)
    • 11.3.4 U.K.
      • 11.3.4.1 U.K. Minimal Residual Disease Testing Market (by Application)
    • 11.3.5 Spain
      • 11.3.5.1 Spain Minimal Residual Disease Testing Market (by Application)
    • 11.3.6 Rest-of-Europe
      • 11.3.6.1 Rest-of-Europe Minimal Residual Disease Testing Market (by Application)
  • 11.4 Asia-Pacific
    • 11.4.1 China
      • 11.4.1.1 China Minimal Residual Disease Testing Market (by Application)
    • 11.4.2 India
      • 11.4.2.1 India Minimal Residual Disease Testing Market (by Application)
    • 11.4.3 Japan
      • 11.4.3.1 Japan Minimal Residual Disease Testing Market (by Application)
    • 11.4.4 South Korea
      • 11.4.4.1 South Korea MRD Testing Market (by Application)
    • 11.4.5 Australia
      • 11.4.5.1 Australia Minimal Residual Disease Testing Market (by Application)
    • 11.4.6 Singapore
      • 11.4.6.1 Singapore Minimal Residual Disease Testing Market (by Application)
    • 11.4.7 Rest-of-APAC (RoAPAC)
      • 11.4.7.1 Rest-of-APAC Minimal Residual Disease Testing Market (by Application)
  • 11.5 Latin America and Middle East
    • 11.5.1 Brazil
      • 11.5.1.1 Brazil Minimal Residual Disease Testing Market (by Application)
    • 11.5.2 Mexico
      • 11.5.2.1 Mexico Minimal Residual Disease Testing Market (by Application)
    • 11.5.3 Saudi Arabia
      • 11.5.3.1 Saudi Arabia Minimal Residual Disease Testing Market (by Application)
    • 11.5.4 Rest-of-Latin America and Middle East
      • 11.5.4.1 Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application)
  • 11.6 Rest-of-the-World (RoW)
      • 11.6.1.1 Rest-of-the-World Minimal Residual Disease Testing Market (by Application)

12 Company Profiles

  • 12.1 Overview
  • 12.2 ICON plc
    • 12.2.1 Company Overview
    • 12.2.2 Role of ICON plc in Global Minimal Residual Disease Testing Market
    • 12.2.3 Key Customers of the Company
    • 12.2.4 Key Competitors of the Company
    • 12.2.5 Financials
    • 12.2.6 Analyst's Perspective
  • 12.3 ARUP Laboratories
    • 12.3.1 Company Overview
    • 12.3.2 Role of ARUP Laboratories in Global Minimal Residual Disease Testing Market
    • 12.3.3 Key Customers of the Company
    • 12.3.4 Key Competitors of the Company
    • 12.3.5 Analyst's Perspective
  • 12.4 Cergentis B.V.
    • 12.4.1 Company Overview
    • 12.4.2 Role of Cergentis B.V. in Global Minimal Residual Disease Testing Market
    • 12.4.3 Key Customers of the Company
    • 12.4.4 Key Competitors of the Company
    • 12.4.5 Analyst's Perspective
  • 12.5 Bio-Rad Laboratories, Inc.
    • 12.5.1 Company Overview
    • 12.5.2 Role of Bio-Rad Laboratories, Inc. in Global Minimal Residual Disease Testing Market
    • 12.5.3 Key Customers of the Company
    • 12.5.4 Key Competitors of the Company
    • 12.5.5 Financials
    • 12.5.6 Key Insights About Financial Health of the Company
    • 12.5.7 Analyst's Perspective
  • 12.6 Mission Bio, Inc.
    • 12.6.1 Company Overview
    • 12.6.2 Role of Mission Bio, Inc. in Global Minimal Residual Disease Testing Market
    • 12.6.3 Key Customers of the Company
    • 12.6.4 Key Competitors of the Company
    • 12.6.5 Recent Developments
    • 12.6.6 Analyst's Perspective
  • 12.7 Guardant Health
    • 12.7.1 Company Overview
    • 12.7.2 Role of Guardant Health in Global Minimal Residual Disease Testing Market
    • 12.7.3 Key Customers of the Company
    • 12.7.4 Key Competitors of the Company
    • 12.7.5 Financials
    • 12.7.6 Key Insights About Financial Health of the Company
    • 12.7.7 Recent Developments
    • 12.7.8 Analyst's Perspective
  • 12.8 Invivoscribe, Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Role of Invivoscribe, Inc. in Global Minimal Residual Disease Testing Market
    • 12.8.3 Key Customers of the Company
    • 12.8.4 Key Competitors of the Company
    • 12.8.5 Recent Developments
    • 12.8.6 Analyst's Perspective
  • 12.9 Laboratory Corporation of America Holdings
    • 12.9.1 Company Overview
    • 12.9.2 Role of Laboratory Corporation of America Holdings in Global Minimal Residual Disease Testing Market
    • 12.9.3 Key Customers of the Company
    • 12.9.4 Key Competitors of the Company
    • 12.9.5 Financials
    • 12.9.6 Analyst's Perspective
  • 12.1 Natera, Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Role of Natera, Inc. in Global Minimal Residual Testing Market
    • 12.10.3 Key Customers of the Company
    • 12.10.4 Key Competitors of the Company
    • 12.10.5 Financials
    • 12.10.6 Key Insights About Financial Health of the Company
    • 12.10.7 Recent Developments
    • 12.10.8 Analyst's Perspective
  • 12.11 NeoGenomics Laboratories, Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Role of NeoGenomics Laboratories, Inc. in Global Minimal Residual Testing Market
    • 12.11.3 Key Customers of the Company
    • 12.11.4 Key Competitors of the Company
    • 12.11.5 Financials
    • 12.11.6 Key Insights About Financial Health of the Company
    • 12.11.7 Recent Developments
    • 12.11.8 Analyst's Perspective
  • 12.12 Opko Health, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Opko Health, Inc. in Global Minimal Residual Disease Testing Market
    • 12.12.3 Key Customers of the Company
    • 12.12.4 Key Competitors of the Company
    • 12.12.5 Financials
    • 12.12.6 Key Insights About Financial Health of the Company
    • 12.12.7 Analyst's Perspective
  • 12.13 Quest Diagnostics Incorporated
    • 12.13.1 Company Overview
    • 12.13.2 Role of Quest Diagnostics Incorporated in Global Minimal Residual Disease Testing Market
    • 12.13.3 Key Customers of the Company
    • 12.13.4 Key Competitors of the Company
    • 12.13.5 Financials
    • 12.13.6 Analyst's Perspective
  • 12.14 Sysmex Corporation
    • 12.14.1 Company Overview
    • 12.14.2 Role of Sysmex Corporation in Global Minimal Residual Disease Testing Market
    • 12.14.3 Key Customers of the Company
    • 12.14.4 Key Competitors of the Company
    • 12.14.5 Financials
    • 12.14.6 Key Insights About Financial Health of the Company
    • 12.14.7 Analyst's Perspective
  • 12.15 Adaptive Biotechnologies Corporation
    • 12.15.1 Company Overview
    • 12.15.2 Role of Adaptive Biotechnologies Corporation in Global Minimal Residual Disease Testing Market
    • 12.15.3 Key Competitors of the Company
    • 12.15.4 Financials
    • 12.15.5 Key Insights About Financial Health of the Company
    • 12.15.6 Recent Developments
    • 12.15.7 Analyst's Perspective
  • 12.16 F. Hoffmann- La Roche Ltd
    • 12.16.1 Company Overview
    • 12.16.2 Role of F. Hoffmann-La Roche Ltd in Global Minimal Residual Disease Testing Market
    • 12.16.3 Key Customers of the Company
    • 12.16.4 Key Competitors of the Company
    • 12.16.5 Financials
    • 12.16.6 Key Insights About Financial Health of the Company
    • 12.16.7 Analyst's Perspective

List of Figures

  • Figure 1: Global Cancer Incidence, 2020
  • Figure 2: New Lymphoma Cases Expected in the U.S., 2022
  • Figure 3: Prevalence of Different Hematological Malignancies Across the U.S. (2018-2021)
  • Figure 4: Global Minimal Residual Disease Testing Market, Impact Analysis
  • Figure 5: Global MRD Testing Market (by Application), $Million, 2021 vs. 2027
  • Figure 6: Global MRD Testing Market (by Hematological Malignancy), $Million, 2021 vs. 2027
  • Figure 7: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2021 vs. 2027
  • Figure 8: Global Minimal Residual Disease Testing Market (by End User), $Million, 2021 vs. 2027
  • Figure 9: Global Minimal Residual Disease Testing Market Snapshot
  • Figure 10: Global MRD Testing Market Segments
  • Figure 11: Global MRD Testing Market: Methodology
  • Figure 12: Primary Research Methodology
  • Figure 13: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 14: Top-Down Approach (Segment-Wise Analysis)
  • Figure 15: Global MRD Testing Market, $Million, 2021-2027
  • Figure 16: Global MRD Testing Market Potential, $Million, 2021-2027
  • Figure 17: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2020
  • Figure 18: Global Incidence of Leukemia (by Region), 2020
  • Figure 19: Incidence of Hematological Malignancies in the U.S. (by Type), 2021
  • Figure 20: New Cases of Hematological Cancer in the U.S. (by Sex), 2021
  • Figure 21: Biomarker Evaluation and Evidentiary Considerations
  • Figure 22: Regulatory Submissions for the Use of Minimal Residual Disease as a Biomarker
  • Figure 23: Laboratory Methods for MRD Detection
  • Figure 24: Classification of In-Vitro Diagnostics in India
  • Figure 25: Methods to Achieve Coverage
  • Figure 26: Supply Chain Analysis of Laboratory Developed Tests
  • Figure 27: Supply Chain Analysis of In-Vitro Diagnostics
  • Figure 28: Share of Key Developments and Strategies, January 2018-May 2022
  • Figure 29: Synergistic Activities Share (by Company), January 2018-May 2022
  • Figure 30: Product Approvals Share (by Company), January 2018-May 2022
  • Figure 31: Product Launches and Updates Share (by Company), January 2018-May 2022
  • Figure 32: Merger and Acquisition Activities Share (by Company), January 2018-May 2022
  • Figure 33: Business Expansion and Funding Activities Share (by Company), January 2018-May 2022
  • Figure 34: Market Share Analysis for Global MRD Testing Market, 2020 and 2021
  • Figure 35: Growth-Share Analysis for Global MRD Testing Market (by Company), 2019
  • Figure 36: Growth-Share Analysis for Global MRD Testing Market (by Technology), 2021-2027
  • Figure 37: Growth-Share Analysis for Global MRD Testing Market (by Application), 2021-2027
  • Figure 38: Growth-Share Analysis for Global MRD Testing Market (by End User), 2021-2027
  • Figure 39: Treatment Stage for MRD Testing
  • Figure 40: Average Number of MRD Tests Per Patient Per Year
  • Figure 41: Average Treatment Duration
  • Figure 42: Perceived Importance of Key Drivers to Improve MRD Testing Adoption
  • Figure 43: Agreement Level with Key Barriers to MRD Testing Adoption
  • Figure 44: Reimbursement Scenario with respect to MRD Testing
  • Figure 45: Price vs. Sensitivity vs. Turnaround Time
  • Figure 46: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2021-2027
  • Figure 47: Global Minimal Residual Disease Testing Market (Flow Cytometry), $Million, 2021-2027
  • Figure 48: Global Minimal Residual Disease Testing Market (Flow Cytometry), Thousand Units, 2021-2027
  • Figure 49: Global Minimal Residual Disease Testing Market (PCR), $Million, 2021-2027
  • Figure 50: Global Minimal Residual Disease Testing Market (PCR), Thousand Units, 2021-2027
  • Figure 51: Global Minimal Residual Disease Testing Market (NGS), $Million, 2021-2027
  • Figure 52: Global Minimal Residual Disease Testing Market (by NGS), Thousand Units, 2021-2027
  • Figure 53: Global Minimal Residual Disease Testing Market (Other Technologies), $Million, 2021-2027
  • Figure 54: Global Minimal Residual Disease Testing Market (Other Technologies), Thousand Units, 2021-2027
  • Figure 55: Global MRD Testing Market (by Application)
  • Figure 56: Global MRD Testing Market (by Application), 2021-2027
  • Figure 57: Global MRD Testing Market (by Hematological Malignancy), 2021 vs. 2027
  • Figure 58: Global Minimal Residual Disease Testing Market (Non-Hodgkin's Lymphoma), $Million, 2021-2027
  • Figure 59: Global Minimal Residual Disease Testing Market (by Non-Hodgkin's Lymphoma Type), $Million, 2021 vs. 2027
  • Figure 60: Global NHL MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 61: Global Minimal Residual Disease Testing Market (Multiple Myeloma), $Million, 2021-2027
  • Figure 62: Global MM MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 63: Global Minimal Residual Disease Testing Market (Acute Lymphoblastic Leukemia), $Million, 2021-2027
  • Figure 64: Global ALL MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 65: Global Minimal Residual Disease Testing Market (Chronic Lymphocytic Leukemia), $Million, 2021-2027
  • Figure 66: Global CLL MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 67: Global Minimal Residual Disease Testing Market (Acute Myeloid Leukemia), $Million, 2021-2027
  • Figure 68: Global AML MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 69: Global Minimal Residual Disease Testing Market (Chronic Myeloid Leukemia), $Million, 2021-2027
  • Figure 70: Global CML MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 71: Global Minimal Residual Disease Testing Market (Hodgkin's Lymphoma), $Million, 2021-2027
  • Figure 72: Global HL MRD Testing Market (by Age), $Million, 2021 vs. 2027
  • Figure 73: Global Minimal Residual Disease Testing Market (Other Leukemia), $Million, 2021-2027
  • Figure 74: Global Minimal Residual Disease Testing Market (by End User), $Million, 2021-2027
  • Figure 75: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics), $Million, 2021-2027
  • Figure 76: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics), Thousand Units, 2021-2027
  • Figure 77: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics) (by Technology), $Million, 2021 vs. 2027
  • Figure 78: Global Minimal Residual Disease Testing Market (Hospitals and Specialty Clinics) (by Technology), Thousand Units, 2021 vs. 2027
  • Figure 79: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories), $Million, 2021-2027
  • Figure 80: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2027
  • Figure 81: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories) (by Technology), $Million, 2021 vs. 2027
  • Figure 82: Global Minimal Residual Disease Testing Market (Diagnostic Laboratories) (by Technology), Thousand Units, 2021 vs. 2027
  • Figure 83: Global Minimal Residual Disease Testing Market (Research Institutions), $Million, 2021-2027
  • Figure 84: Global Minimal Residual Disease Testing Market (Research Institutions), Thousand Units, 2021-2027
  • Figure 85: Global Minimal Residual Disease Testing Market (Research Institutions) (by Technology), $Million, 2021 vs. 2027
  • Figure 86: Global Minimal Residual Disease Testing Market (Research Institutions) (by Technology), Thousand Units, 2021 vs. 2027
  • Figure 87: Global Minimal Residual Disease Testing Market (Other End Users), $Million, 2021-2027
  • Figure 88: Global Minimal Residual Disease Testing Market (Other End Users), Thousand Units, 2021-2027
  • Figure 89: Global Minimal Residual Disease Testing Market (Other End Users) (by Technology), $Million, 2021 vs.2027
  • Figure 90: Global Minimal Residual Disease Testing Market (Other End Users) (by Technology), Thousand Units, 2021 vs. 2027
  • Figure 91: Global Minimal Residual Disease Testing Market (by Region), $Million, 2021 and 2027
  • Figure 92: North America: Market Dynamics
  • Figure 93: North America Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 94: North America Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027
  • Figure 95: U.S. Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 96: U.S. Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 97: U.S. Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 98: Growth-Share Analysis for the U.S. Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 99: Canada Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 100: Canada Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 101: Canada Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 102: Growth-Share Analysis for Canada Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 103: Europe: Market Dynamics
  • Figure 104: Europe Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 105: Europe Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027
  • Figure 106: Germany Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 107: Germany Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 108: Germany Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 109: Growth-Share Analysis for Germany Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 110: Italy Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 111: Italy Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 112: Italy Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 113: Growth-Share Analysis for Italy Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 114: France Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 115: France Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 116: France Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 117: Growth-Share Analysis for France Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 118: U.K. Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 119: U.K. Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 120: U.K. Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 121: Growth-Share Analysis for the U.K. Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 122: Spain Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 123: Spain Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 124: Spain Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 125: Growth-Share Analysis for Spain Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 126: Rest-of-Europe Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 127: Rest-of-Europe Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 128: Rest-of-Europe Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 129: Growth-Share Analysis for Rest-of-Europe Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 130: Asia-Pacific: Market Dynamics
  • Figure 131: Asia-Pacific Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 132: Asia-Pacific Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2027
  • Figure 133: China Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 134: China Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 135: China Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 136: Growth-Share Analysis for China Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 137: India Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 138: India Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 139: India Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 140: Growth-Share Analysis for India Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 141: Japan Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 142: Japan Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 143: Japan Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 144: Growth-Share Analysis for Japan Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 145: South Korea Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 146: South Korea Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 147: South Korea Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 148: Growth Share Analysis for South Korea MRD Testing Market (by Application), 2021-2027
  • Figure 149: Australia Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 150: Australia Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 151: Australia Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 152: Growth-Share Analysis for Australia Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 153: Singapore Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 154: Singapore Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 155: Singapore Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 156: Growth-Share Analysis for Singapore Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 157: Rest-of-APAC Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 158: Rest-of-APAC Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 159: Rest-of-APAC Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 160: Growth-Share Analysis for Rest-of-APAC Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 161: Latin America: Market Dynamics
  • Figure 162: Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 163: Latin America and Middle East Minimal Residual Disease Testing Market (by Country), $Million, 2021 vs. 2027
  • Figure 164: Brazil Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 165: Brazil Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 166: Brazil Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 167: Growth-Share Analysis for Brazil Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 168: Mexico Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 169: Mexico Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 170: Mexico Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 171: Growth-Share Analysis for Mexico Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 172: Saudi Arabia Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 173: Saudi Arabia Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 174: Saudi Arabia Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 175: Growth-Share Analysis for Saudi Arabia Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 176: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 177: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 178: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 179: Growth-Share Analysis for Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 180: Rest-of-the-World Minimal Residual Disease Testing Market, $Million, 2021-2027
  • Figure 181: Rest-of-the-World Minimal Residual Disease Testing Market (by Application), $Million, 2021-2027
  • Figure 182: Rest-of-the-World Minimal Residual Disease Testing Market (by Hematological Malignancy), $Million, 2021-2027
  • Figure 183: Growth-Share Analysis for Rest-of-the-World Minimal Residual Disease Testing Market (by Application), 2021-2027
  • Figure 184: Total Number of Companies Profiled
  • Figure 185: ICON plc: Overall Product Portfolio
  • Figure 186: ICON plc: Overall Financials, $Million, 2019-2021
  • Figure 187: ICON plc: Revenue (by Region), $Million, 2019-2021
  • Figure 188: ARUP Laboratories: Product Portfolio
  • Figure 189: Cergentis B.V.: Product Portfolio
  • Figure 190: Bio-Rad Laboratories, Inc.: Product Portfolio
  • Figure 191: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 192: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 193: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 194: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 195: Mission Bio, Inc.: Product Portfolio
  • Figure 196: Guardant Health: Portfolio
  • Figure 197: Guardant Health: Overall Financials, $Million, 2019-2021
  • Figure 198: Guardant Health: Revenue (by Segment), $Million, 2019-2021
  • Figure 199: Guardant Health: Revenue (by Region), $Million, 2019-2021
  • Figure 200: Guardant Health: R&D Expenditure, $Million, 2019-2021
  • Figure 201: Invivoscribe, Inc.: Product Portfolio
  • Figure 202: Laboratory Corporation of America Holdings: Product Portfolio
  • Figure 203: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
  • Figure 204: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021
  • Figure 205: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021
  • Figure 206: Natera, Inc.: Portfolio
  • Figure 207: Natera, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 208: Natera, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 209: Natera, Inc.: Sales (by Region), $Million, 2019-2021
  • Figure 210: Natera, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 211: NeoGenomics Laboratories, Inc.: Portfolio
  • Figure 212: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 213: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 214: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 215: Opko Health: Portfolio
  • Figure 216: Opko Health, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 217: Opko Health, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 218: Opko Health, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 219: Quest Diagnostics Incorporated: Product Portfolio
  • Figure 220: Quest Diagnostics Incorporated: Overall Financials, $Million, 2019-2021
  • Figure 221: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2019-2021
  • Figure 222: Sysmex Corporation: Product Portfolio
  • Figure 223: Sysmex Corporation: Overall Financials, $Million, 2019-2021
  • Figure 224: Sysmex Corporation: Revenue (by Business Segment), $Million, 2019-2021
  • Figure 225: Sysmex Corporation: Revenue (by Region), $Million, 2019-2021
  • Figure 226: Sysmex Corporation R&D Expenditure, $Million, 2019-2021
  • Figure 227: Adaptive Biotechnologies Corporation: Product Portfolio
  • Figure 228: Adaptive Biotechnologies Corporation: Overall Financials, $Million, 2019-2021
  • Figure 229: Adaptive Biotechnologies Corporation: Revenue (by Business Segment), $Million, 2019-2021
  • Figure 230: Adaptive Biotechnologies Corporation R&D Expenditure, $Million, 2019-2021
  • Figure 231: F. Hoffmann-La Roche Ltd: Portfolio
  • Figure 232: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
  • Figure 233: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
  • Figure 234: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
  • Figure 235: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021

List of Tables

  • Table 1: Likert Scale
  • Table 2: Impact Analysis of Market Drivers
  • Table 3: Impact Analysis of Market Restraints
  • Table 4: Current Research Grants and Funding in the U.S., 2021
  • Table 5: MRD False Positive and Negative (by Relapse State)
  • Table 6: List of Approved MRD Tests by Major Players
  • Table 7: List of Launched MRD Tests (by Major Players)
  • Table 8: Key Notable Developments
  • Table 9: Key Notable Developments
  • Table 10: Comparison of FDA and EMA Draft Guidance
  • Table 11: Registration Criteria for IVD Medical Devices as per CFDA
  • Table 12: Key Coverage Providers for Hematologic Malignancies Testing
  • Table 13: Key Products Offered Based on Flow Cytometry
  • Table 14: Key Products Offered Based on PCR
  • Table 15: Key Products Offered Based on NGS